Investigation of the influence of body weight index to the result of therapeutic erythrocytapheresis in patients with polycythemia vera

被引:7
作者
Bai, Jie [1 ,2 ,3 ]
Zhang, Lei [1 ,2 ,3 ]
Hu, Xiao [1 ,2 ,3 ]
Xue, Yangping [1 ,2 ,3 ]
Long, Fenglei [1 ,2 ,3 ]
Zhang, Bin [1 ,2 ,3 ]
Yan, Shi [1 ,2 ,3 ]
机构
[1] Chinese Acad Med Sci, Blood Transfus Ctr, Inst Hematol, State Key Lab Expt Hematol, Tianjin 300020, Peoples R China
[2] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China
[3] Peking Union Med Coll, Tianjin 300020, Peoples R China
关键词
Polycythemia vera; Therapeutic erythrocytapheresis; Body weight index; Reverse response; TYROSINE KINASE JAK2; ESSENTIAL THROMBOCYTHEMIA; RISK-FACTORS; THROMBOSIS; MUTATION; LEUKOCYTOSIS;
D O I
10.1016/j.transci.2012.07.017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We investigated the correlation between body weight index (BWI) and the effective power of erythrocytapheresis in patients with polycythemia vera (PV) who received therapeutic erythrocytapheresis (TEA). Furthermore, the risk factors of the adverse events related to erythroapheresis therapy were analyzed. Two hundred and seventeen cycles of therapeutic erythrocytapheresis were carried out in 139 patients with PV (Hct). The correlation between the BWI and the difference of hematocrit before and after therapeutic erythrocytapheresis (Delta Hct) was analyzed by the Pearson correlation analysis method. Logistic regression analysis was used to study the risk factors of adverse events for TEA. We observed a positive correlation between the BWI and Delta Hct. BWI over 15 ml/kg, inlet velocity of the apheresis procedure over 45 ml/min and an age older than 50 years were the risk factors of adverse events of TEA. The results suggested that BWI was a sensitive index to estimate the effective power and adverse events of TEA. The rate of adverse events of TEA might be reduced by maintaining the BWI below the dangerous threshold of 15 ml/kg and the inlet velocity of the apheresis procedure below 45 ml/min especially in patients older than 50 years of age. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:295 / 299
页数:5
相关论文
共 23 条
[1]   Who Needs a Therapeutic Phlebotomy? [J].
Antle, Emily .
CLINICAL JOURNAL OF ONCOLOGY NURSING, 2010, 14 (06) :694-696
[2]   Risk factors of long-term incidences of thrombosis, myelofibrosis and evolution into malignance in polycythemia vera: a single center experience from China [J].
Bai, Jie ;
Xue, Yangping ;
Ye, Lei ;
Yao, Jianfeng ;
Zhou, Chunlin ;
Shao, Zonghong ;
Qian, Linsheng ;
Yang, Renchi ;
Li, Haiyan ;
Zhang, Hongyun ;
Zheng, Yizhou .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (05) :530-535
[3]   Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].
Baxter, EJ ;
Scott, LM ;
Campbell, PJ ;
East, C ;
Fourouclas, N ;
Swanton, S ;
Vassiliou, GS ;
Bench, AJ ;
Boyd, EM ;
Curtin, N ;
Scott, MA ;
Erber, WN ;
Green, AR .
LANCET, 2005, 365 (9464) :1054-1061
[4]   Erythropoiesis in polycythemia vera is hyper-proliferative and has accelerated maturation [J].
Bruchova, Hana ;
Yoon, Donghoon ;
Agarwal, Archana M. ;
Swierczek, Sabina ;
Prchal, Josef T. .
BLOOD CELLS MOLECULES AND DISEASES, 2009, 43 (01) :81-87
[5]   Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status [J].
Carobbio, Alessandra ;
Finazzi, Guido ;
Guerini, Vittoria ;
Spinelli, Orietta ;
Delaini, Federica ;
Marchioli, Roberto ;
Borrelli, Giovanna ;
Rambaldi, Alessandro ;
Barbui, Tiziano .
BLOOD, 2007, 109 (06) :2310-2313
[6]  
Catherine L, 2006, BLOOD, V108, P1652
[7]   Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia [J].
Elliott, MA ;
Tefferi, A .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (03) :275-290
[8]   Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: The role of neutrophils [J].
Falanga, A ;
Marchetti, M ;
Barbui, T ;
Smith, CW .
SEMINARS IN HEMATOLOGY, 2005, 42 (04) :239-247
[9]   Alternative method to determine the hematocrit of red blood cell units: a potential use in the apheresis unit [J].
Farrell, Sharon B. ;
Shelat, Suresh G. ;
Kim, Haewon C. ;
Drew, Christa .
TRANSFUSION, 2009, 49 (06) :1255-1258
[10]   Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status [J].
Finazzi, Guido ;
Rambaldi, Alessandro ;
Guerini, Vittoria ;
Carobbo, Alessandra ;
Barbui, Tiziano .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (01) :135-136